Obatoclax
As of the edition of 20 October 2026, Obatoclax is a small molecule: stopped in 2018; acts on BCL2, BCL2A1 and BCL2L1 and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Small molecule
- Registered trials
- 19, 8 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Heart and blood vessels; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
12 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product12 company-target rows are on route A because of Obatoclax.
See the 12 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 2 | 0 | 3 |
| Phase 2 | 13 | 9 | 0 | 4 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 19 |